Ongoing Studies for Patients with Relapsed/Refractory AML

February 23, 2018
Daniel J. DeAngelo, MD, PhD

Daniel J. DeAngelo, MD, PhD, associate professor of medicine at Harvard Medical School, and a member of the Adult Leukemia Program at the Dana-Farber Cancer Institute, discusses some of the clinical trials currently ongoing for patients with relapsed/refractory acute myeloid leukemia (AML). DeAngelo says he primarily uses targeted and combination therapies.